ATRIUM THERAPEUTICS INC (RNA)
Health Care · RNA therapeutics for rare genetic cardiomyopathies · NASDAQ
Atrium is an early-stage biotech pioneering antibody-conjugated RNA therapeutics to treat rare genetic cardiomyopathies by silencing disease-driving genes in the heart.
What ATRIUM THERAPEUTICS INC does
Atrium Therapeutics is a biopharmaceutical company pioneering RNA-based therapeutics for cardiomyopathies using a proprietary targeted RNA delivery platform. The company combines monoclonal antibody-based tissue selectivity with oligonucleotide precision to target previously undruggable genetic drivers of heart disease, with an initial focus on rare genetic cardiology targets including PRKAG2 syndrome and PLN cardiomyopathy.
Themes: ["RNA therapeutics","Rare genetic cardiomyopathies","Targeted drug delivery","Precision cardiology"]
Fundamentals
- Price$12.91 as of 2026-07-09 close
- Market cap$229M as of 2026-07-10
- 1-year return-54.3% as of 2026-07-09 close
- Net margin-172.9% as of 2026-07-10
- ROE-40.3% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+22.0% as of 2026-07-10
- Beta0.98 as of 2026-07-10
Key risks (from latest filing)
["Early-stage pipeline with lead candidates (ATR 1072, ATR 1086) in preclinical development; first IND filing expected in H2 2026 with no clinical data yet","Company was recently spun off from Avidity Biosciences and is operating as a standalone entity for the first time, with no established commercial infrastructure or revenue","Dependency on proprietary RNA delivery technology platform; any failure in platform development or manufacturing scale-up could halt multiple pipeline programs"]
Competitors & peers
- Arrowhead Research (ARWR)
- Alnylam Pharmaceuticals (ALNY)
- Ionis Pharmaceuticals (IONS)
- Regeneron Pharmaceuticals (REGN)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.